619 results on '"Kim, H.T."'
Search Results
2. Value of 68Ga-PSMA PET/CT compared to mpMRI for primary tumor characterization based on radical prostatectomy histopathology
3. 35 A novel therapeutic approach using taurodeoxycholate, a GPCR19R agonist, for atopic dermatitis: a randomized, double-blind, placebo-controlled phase II trial with identification of predictive biomarkers
4. Commissioning of vacuum pumping devices of the second KSTAR neutral beam injection system
5. Design and CFD analysis of hypervapotron-typed ion dump for KSTAR NBI-2 system
6. High heat flux test and cooling effect of tungsten brazed mockups with swirl tube
7. Low loss polypropylene-silicon composites for millimetre wave applications
8. An assessment of axial pre-compression for the KSTAR central solenoid
9. Development of the new KSTAR helium distribution box
10. Mixed convection around calandria tubes in a ¼ scale CANDU-6 moderator circulation tank
11. The thermal interaction of a buoyant plume from a calandria tube with an oblique jet
12. High heat flux test of tungsten brazed mock-ups developed for KSTAR divertor
13. Castellated tungsten plasma-facing components exposed to H-mode plasma in KSTAR
14. Epsin deficiency promotes lymphangiogenesis through regulation of VEGFR3 degradation in diabetes
15. Data from Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype
16. Supplementary Figures 1 - 5, Table 1 from Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
17. Data from Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
18. Supplementary Figures 1 - 11, Tables 1 - 3 from Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype
19. CCR Translation for This Article from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
20. Supplementary Materials, Tables 1-2, Figures 1-11 from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
21. Supplementary Tables 1-2, Figures 1-12 from PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
22. Data from PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
23. Supplementary Figures 1 - 11, Tables 1 - 3 from Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype
24. Data from Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
25. Supplementary Figures 1 - 5, Table 1 from Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
26. Data from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
27. CCR Translation for This Article from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
28. Supplementary Materials, Tables 1-2, Figures 1-11 from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
29. Supplementary Tables 1-2, Figures 1-12 from PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
30. Data from PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
31. 207MO Efficacy and safety of IMC-001, anti-PD-L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type (R/R ENKTL)
32. Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
33. Generation of Ni-like Ag X-Ray Laser and High-Order Harmonics Forward Harmonic Seeded X-Ray Laser
34. On the Way Towards a High Repetition Rate X-Ray Laser
35. Advances in prediction of tokamak experiments with theory-based models
36. A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer
37. Characterization of the thermal conductivity of EB-PVD ZrO2–Y2O3 coatings with a pulsed thermal imaging method
38. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome
39. The KSTAR plasma facing components for 2010 operation
40. Fabrication and installation of KSTAR in-vessel control coils
41. Development of KSTAR in-vessel components and heating systems
42. Improvement of initial vacuum condition along 2008–2010 KSTAR campaign by vessel baking
43. Structured three-dimensional co-culture of mesenchymal stem cells with chondrocytes promotes chondrogenic differentiation without hypertrophy
44. First boronization in KSTAR
45. P47.08 A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
46. SHIP limits immunoregulatory capacity in the T-cell compartment
47. A study on thermal stress deformation using analytical methods based on the temperature distribution of storage material in a rotary air-preheater
48. Wall conditioning of the KSTAR vacuum vessel
49. Plasma control system for “Day-One” operation of KSTAR tokamak
50. Overview of the KSTAR vacuum pumping system
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.